Seely Lynn 4

What Happened
Seely Lynn, President & CEO and a director of Lyell Immunopharma, sold 7,455 shares on 2026-02-11 in an open-market/private sale. The reported weighted-average sale price was $23.39 per share (sale price range $23.3939–$24.7850), generating proceeds of about $174,372. The filing notes the shares were sold to satisfy tax-withholding obligations arising from settlement of performance-based vested restricted stock units.

Key Details

• Transaction date: 2026-02-11; Form 4 filed 2026-02-12 (timely; within SEC 2-business-day requirement).
• Transaction type/code: Sale (S).
• Shares sold: 7,455; weighted-average price reported: $23.39; total proceeds ≈ $174,372.
• Price range for shares sold: $23.3939 to $24.7850 (per Footnote F2; full per-price breakdown available on request).
• Reason for sale (Footnote F1): automatic sale to cover tax withholding on vested performance RSUs.
• Shares owned after the transaction: not specified in the provided filing.

Context
This was a sale to cover tax withholding related to vested performance RSUs — a common, routine form of insider sale that does not necessarily signal a change in insider sentiment about the company. Footnote F2 indicates the reported price is a weighted average and that the issuer or reporting person can provide the exact number of shares sold at each specific price if requested.